Armata Pharmaceuticals (ARMP) Accumulated Expenses (2014 - 2026)

Armata Pharmaceuticals has disclosed Accumulated Expenses across 13 years of filings, most recently posting $2.8 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $2.8 million, up 108.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.8 million (up 108.98% YoY), and the FY2025 annual result was $2.2 million, down 3.9% from the prior year.
• Accumulated Expenses came in at $2.8 million for Q1 2026 at Armata Pharmaceuticals, up from $2.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $2.8 million in Q1 2026 to a low of $768000.0 in Q4 2023.
• The 5-year median for Accumulated Expenses is $1.6 million (2025), against an average of $1.6 million.
• Across the five-year window, Accumulated Expenses plunged 57.99% in 2023 and soared 196.88% in 2024, its largest moves.
• Armata Pharmaceuticals' Accumulated Expenses stood at $1.8 million in 2022, then slumped by 57.99% to $768000.0 in 2023, then jumped by 196.88% to $2.3 million in 2024, then slipped by 3.9% to $2.2 million in 2025, then grew by 28.48% to $2.8 million in 2026.
• The last three Accumulated Expenses figures came in at $2.8 million (Q1 2026), $2.2 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.